Diplomat supports patients nationwide who receive intravenous inhibitors of tumor necrosis factor (TNF)-alpha for inflammatory conditions. These include Remicade® (infliximab), Simponi Aria® (golimumab), and biosimilars of infliximab.
TNF-alpha is a protein that helps the body regulate its immune system. Too much can lead to inflammatory diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Intravenous TNF-alpha inhibitors can reduce inflammation and stop disease progression, relieving patients’ sometimes life-altering symptoms.
Diplomat is committed to breaking down barriers to care—including providing home administration of intravenous TNF-alpha inhibitors, securing third-party financial assistance, and working on prior authorizations and appeals. We are here for patients 24/7, ready to answer clinical questions and offer support. We do whatever it takes to help patients manage their therapy.